Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4

Core Insights - Nexalin Technology, Inc. is hosting a webinar on December 4, 2025, to discuss its innovative approach to mental healthcare using its proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology [1][2] - The company is positioned in a $537 billion mental health market, with international regulatory approvals and U.S. expansion plans underway [2] Company Overview - Nexalin develops non-invasive neurostimulation products aimed at addressing the global mental health epidemic, utilizing bioelectronic frequency-based medical technology [4] - The company's devices, including the Gen-2 and Gen-3 models, are designed to penetrate deep brain structures associated with mental health disorders, enhancing patient response without adverse side effects [4] - The Gen-2 15 milliamp neurostimulation device has received approvals in multiple countries, including China, Brazil, Israel, and Oman [4] Webinar Details - The webinar will feature CEO Mark White, who will present clinical evidence and updates on the Gen-3 HALO™ Clarity headset and Virtual Clinic model for scalable at-home treatment [2] - A live Q&A session will follow the presentation, allowing investors to engage directly with the CEO [2][3]